<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000658</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 142</org_study_id>
    <secondary_id>11117</secondary_id>
    <nct_id>NCT00000658</nct_id>
  </id_info>
  <brief_title>A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the impact of dose intensity on tumor response and survival in patients with&#xD;
      HIV-associated non-Hodgkin's lymphoma (NHL).&#xD;
&#xD;
      HIV-infected patients are at increased risk for developing intermediate and high-grade NHL.&#xD;
      While combination chemotherapy for aggressive B-cell NHL in the absence of immunodeficiency&#xD;
      is highly effective, the outcome of therapy for patients with AIDS-associated NHL has been&#xD;
      disappointing. Treatment is frequently complicated by the occurrence of multiple&#xD;
      opportunistic infections, as well as the presence of poor bone marrow reserve, making the&#xD;
      administration of standard doses of chemotherapy difficult. A recent study was completed&#xD;
      using a low-dose modification of the standard mBACOD (cyclophosphamide, doxorubicin,&#xD;
      vincristine, bleomycin, dexamethasone, methotrexate ) treatment. A 46 percent response rate&#xD;
      was observed in patients treated with this combination of chemotherapeutic agents, with a&#xD;
      number of durable remissions and reduced toxicity when compared to previous experience with&#xD;
      more standard treatments. A subsequent study showed similar effectiveness using a lower dose&#xD;
      of methotrexate administered on day 15. It is hoped that the use of sargramostim&#xD;
      (granulocyte-macrophage colony-stimulating factor; GM-CSF) will improve bone marrow function&#xD;
      and allow for administration of a higher dose of chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-infected patients are at increased risk for developing intermediate and high-grade NHL.&#xD;
      While combination chemotherapy for aggressive B-cell NHL in the absence of immunodeficiency&#xD;
      is highly effective, the outcome of therapy for patients with AIDS-associated NHL has been&#xD;
      disappointing. Treatment is frequently complicated by the occurrence of multiple&#xD;
      opportunistic infections, as well as the presence of poor bone marrow reserve, making the&#xD;
      administration of standard doses of chemotherapy difficult. A recent study was completed&#xD;
      using a low-dose modification of the standard mBACOD (cyclophosphamide, doxorubicin,&#xD;
      vincristine, bleomycin, dexamethasone, methotrexate ) treatment. A 46 percent response rate&#xD;
      was observed in patients treated with this combination of chemotherapeutic agents, with a&#xD;
      number of durable remissions and reduced toxicity when compared to previous experience with&#xD;
      more standard treatments. A subsequent study showed similar effectiveness using a lower dose&#xD;
      of methotrexate administered on day 15. It is hoped that the use of sargramostim&#xD;
      (granulocyte-macrophage colony-stimulating factor; GM-CSF) will improve bone marrow function&#xD;
      and allow for administration of a higher dose of chemotherapy.&#xD;
&#xD;
      Patients are randomized to one of two treatment groups. Patients are stratified for (1)&#xD;
      presence or absence of a prior AIDS diagnosis, (2) Karnofsky performance status of 70 or&#xD;
      greater and lower than 70. Treatment includes prophylaxis for meningeal lymphoma and&#xD;
      Pneumocystis carinii pneumonia. Patients on low-dose mBACOD who experience neutropenia may be&#xD;
      given rGM-CSF until the absolute neutrophil count improves. AZT may be initiated at the&#xD;
      completion of chemotherapy for all patients in complete remission at that time.&#xD;
&#xD;
      PER AMENDMENT 5/30/95: This trial was closed to accrual on 11/7/94 on the recommendation of&#xD;
      the Data and Safety Monitoring Board (DSMB), because the non-significant difference in&#xD;
      survival between the 2 treatment groups was not expected to change with further enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">February 1996</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>250</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  PCP prophylaxis with Bactrim, aerosolized pentamidine, or dapsone.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        ddI, except when patient is also taking allopurinol.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Diagnosis of HIV seropositivity and non-Hodgkin's lymphoma.&#xD;
&#xD;
          -  Ability to give informed consent and willingness to comply with all procedures and&#xD;
             visit schedule.&#xD;
&#xD;
          -  If between ages of 12 and 18 must receive care under direct supervision of a pediatric&#xD;
             oncologist, and have consent of parent, guardian, or person with power of attorney.&#xD;
&#xD;
          -  Participation in clinical trials of other antiretroviral agents is at the discretion&#xD;
             of the investigator and individual patient.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Active opportunistic infection, excluding Mycobacterium avium complex, requiring&#xD;
             antibiotic therapy.&#xD;
&#xD;
          -  Another prior or current malignancy, excepting curatively treated cervical or basal&#xD;
             cell carcinoma.&#xD;
&#xD;
          -  Kaposi's sarcoma if rapidly progressive, with visceral involvement, or causing&#xD;
             peripheral edema.&#xD;
&#xD;
          -  Primary central nervous system lymphoma.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine (AZT) or any antiretroviral agent unless allowed by investigator. ddI is&#xD;
             allowed except when also taking allopurinol.&#xD;
&#xD;
        Systemic myelosuppressive drugs, including trimethoprim/sulfamethoxazole (T/S),&#xD;
        pyrimethamine/sulfa, or ganciclovir.&#xD;
&#xD;
        -&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Active opportunistic infection, excluding Mycobacterium avium complex, requiring&#xD;
             antibiotic therapy.&#xD;
&#xD;
          -  Another prior or current malignancy, excepting curatively treated cervical or basal&#xD;
             cell carcinoma.&#xD;
&#xD;
          -  Kaposi's sarcoma if rapidly progressive, with visceral involvement, or causing&#xD;
             peripheral edema.&#xD;
&#xD;
          -  Primary central nervous system lymphoma.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Immunomodulating agents within 2 weeks of study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Chemotherapy.&#xD;
&#xD;
        Radiation therapy as outlined in protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L Kaplan</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>AA Levine</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>DJ Straus</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>USC CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900331079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>462025250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Med. Ctr., ACTG CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess - East Campus A0102 CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bmc Actg Crs</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Buffalo, Erie County Medical Ctr.</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med. Ctr. (Mt. Sinai)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Ctr.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>275997215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>432101228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. of the Univ. of Pennsylvania CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitt CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, Herndier B, Northfelt DW, Huang J, Tulpule A, Levine AM. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997 Jun 5;336(23):1641-8. doi: 10.1056/NEJM199706053362304.</citation>
    <PMID>9171066</PMID>
  </reference>
  <reference>
    <citation>Kaplan L, et al. Randomized trial of standard dose mBACOD with GM-CSF vs reduced dose mBACOD for systemic HIV-associated lymphoma: ACTG 142. Proc Annu Meet Am Assoc Cancer Res. 1995;14:A818</citation>
  </reference>
  <reference>
    <citation>Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol. 1998 Nov;16(11):3601-6. doi: 10.1200/JCO.1998.16.11.3601.</citation>
    <PMID>9817281</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>M-BACOD protocol</keyword>
  <keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Allopurinol</keyword>
  <keyword>Antineoplastic Agents, Combined</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

